As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Acquista questo ebook e ricevine 1 in più GRATIS!
Formato PDF ● Pagine 444 ● ISBN 9781466579705 ● Casa editrice CRC Press ● Pubblicato 2013 ● Scaricabile 6 volte ● Moneta EUR ● ID 2715426 ● Protezione dalla copia Adobe DRM
Richiede un lettore di ebook compatibile con DRM